CN109511649A - A kind of room temperature machine perfusion system that can expand for liver source - Google Patents
A kind of room temperature machine perfusion system that can expand for liver source Download PDFInfo
- Publication number
- CN109511649A CN109511649A CN201811392862.8A CN201811392862A CN109511649A CN 109511649 A CN109511649 A CN 109511649A CN 201811392862 A CN201811392862 A CN 201811392862A CN 109511649 A CN109511649 A CN 109511649A
- Authority
- CN
- China
- Prior art keywords
- liver
- perfusion
- liquid
- perfusion system
- perfusate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0242—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components
- A01N1/0247—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components for perfusion, i.e. for circulating fluid through organs, blood vessels or other living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Mechanical Engineering (AREA)
- Thermal Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The room temperature machine perfusion system for liver source can be expanded the present invention provides one kind, the machine perfusion system includes Central Processor Module, Power Component, liver storage assembly, liquid circulation component, monitoring assembly and liquid collection assembly, the liquid circulation component includes liver perfusate memory, liver perfusate is stored in the liver perfusate memory, the liver perfusate contains naringenin derivative, and does not contain red blood cell.
Description
Technical field
The invention belongs to Design for Medical Device manufacturing technology fields, and in particular to one kind can expand the room temperature for liver source
Machine perfusion system.
Background technique
China is the high-incidence country of hepatopathy, according to " 2013 China Health statistical yearbook " and " China's tumour registration annual report ", disease
Virus hepatitis year neopathy number 1,370,000, occupy Class A and B infectious diseases first place；Liver cancer year new cases are 35.5 ten thousand, and annual death rate is high
Up to 26.26/10 ten thousand, malignant tumour second is occupied；Become influence in terms of 10,000,000,000 yuan by the health expenditure number of hepatopathy every year
National health, economy, the serious problems of social development.With orthotopic liver transplantation technology, Perioperative Care, efficient immunosupress
Drug is constantly progressive, and liver transfer operation, which has become, saves that End-stage liver disease patient is reliable, effective means.However, with orthotopic liver transplantation
The surge of number of cases becomes increasingly conspicuous for the problem of liver relative shortage.According to statistics, there are about 15% patients because of aggravation or dead every year
It dies and waits list to reject from liver transfer operation.For the shortage of liver, forcing organ transplant doctor constantly to expand can have for safety
Effect transplanting for liver standard, therefore, some not up to ideal donors are also increasingly used in liver transfer operation for liver.It does not reach
" widened ideal is for liver ", " Marginal donor liver " are also referred to as liver to ideal donor.This kind of liver includes DCD for liver, advanced age
For liver, fatty liver for liver, blood group incompatibility for liver and with communicable disease for liver.
DCD is contributed for liver, i.e. liver death liver, is one of the effective way solved for liver critical shortage.International
DCD donor is divided into controllable (M-III) and uncontrollable (M-1, M-II, M-IV, M-V) two by Dutch Maastrichit classification standard
Big type, wherein controllable type refers to by serious irreversible damage, but is also not up to a full set of Medicine standard of brain death, through family
Belong to and agreeing to, in a planned way remove life support, waiting for death occurs." Chinese liver death organ donation operating instructions " is by organ
Donation is divided into 3 classes: C-I i.e. International standardization brain death organ donation；C-II, that is, International standardization DCD, including M-I~M-V；C-
The double dead organ donations of III, that is, heart and brain, have met DBD standard though referring to, have lacked in view of Brain Death Legislation, now still pressed DCD program
Implement.New viewpoint thinks that warm ischemia time should be calculated since stoping jumping the clinical low blood pressure of appearance rather than liver.It can be seen that
Any DCD is likely to face the longer problem of warm ischemia time for liver type, especially by CPR or not
Controllable type DCD donor will undergo the low blood pressure of long period to hit, and serious damage is for liver function.Studies have shown that warm ischemia time
And cold preservation time has a major impact DCD Donor liver quality and receptor prognosis.The interruption and metabolism of oxygen and nutriment source
The accumulation of product may be to lead to the most important factor of Warm ischemia injury, and inevitable outcome is the energy metabolism impairment of cell, liver
It organizes atriphos (ATP) seriously to reduce even to exhaust, total adenine nucleotides reduce sharply, and it is raw to further cause oxygen radical
At, intracellular calcium overload, cell and crganelle function get muddled, Apoptosis.
There are 3 only stage which must be passed bies in liver transplantation: (1) saving the last stage: being obtained including donor management and for liver；(2) it protects
Deposit the stage: including for liver flushing and storage in vitro；(3) the Reperfu- sion stage.Each stage can cause damage and shadow to graft
Ring the prognosis of liver transplant recipients.The damage for saving the last stage is known as damage before saving, and refers to underlying diseases existing for donor itself
And donor operation is damaged caused by graft, this partial injury can contribute standard and careful skilled by reasonable liver
Surgical procedure avoids as far as possible.The damage in preservation stage is the damage undergone before for hepatic vascular exclusion to Reperfu- sion, this part
Damage can only be tried to mitigate but be not avoided that.Cold preserved injury is preservation stage main damage type, and main cause is to save
Endothelial cell oedema and acid poisoning caused by the low temperature of process, anoxic.The damage in Reperfu- sion stage damages after belonging to preservation, occurs
There are two the stages: the 1st stage is characterized by immune system activation and oxidative stress；2nd stage with inflammatory cell, cell factor and
Adhesion factor disorder is characterized.Due to DCD for liver compared to DBD for normal sources such as livers for liver, experienced the long period
Hot ischemic is easier that ischemical reperfusion injury occurs in inhibiting engineering, leads to irreversible damage occur for liver, and can not
Meet the requirement of clinical transplantation.Currently, scholars (can not keep away from donor pretreatment, improvement pulmonary preservation surgical technic respectively
Exempt from the damage of low blood pressure phase), optimization organ store method, receptor agents intervention (influence body other systems function) etc. effort
It attempts to improve DCD Donor liver quality, shortens hot/cold Ischemia Time, extend liver and be resistant to the ischemic time limit, moved to improve DCD for liver
Plant effect, wherein optimization organ store method became and most applies because of the advantages that its applicability is wide, feasibility is strong, significant effect
The break-through point of prospect.
Room temperature machine perfusion is to provide power in room temperature (37 DEG C or so) condition by machine and form closed circuit
Continue to be pumped into perfusion liquid in for liver, remove metabolic waste while metabolism substrate is provided, to mitigate acquisition and save for liver
Damage in the process improves Donor liver quality, extends the holding time of in vitro liver.Hypothermic machine perfusion have device simple, at
This more low advantage.The feature of room temperature machine perfusion maximum is that filling temperature is consistent with body body temperature, is persistently mended by perfusion liquid
Metabolism substrate and supply oxygen are filled to imitate liver perfusion under physiological status, to reduce tissue damage as far as possible.It is most at present
Scholar thinks that the perfusion liquid of room temperature machine perfusion need to be based on whole blood, dilution and test tube of hepari, pH balance blood, fills
Can have the function of transport oxygen after red blood cell is added in fluid injection, and can maximize and imitate perfusion liquid property under physiological status, energy
Enough delay the generation of interstitial edema during machine perfusion.Dries etc. has determined the perfusion liquid ingredient of room temperature machine perfusion for the first time
And its proportion, complete nutrients matter, oxygen and protective substance needed for as meeting a normal liver metabolism, including
Nutrient solution, various trace elements, antibiotic etc. is added in formula based on Red Blood Cells Concentrate, blood plasma, albumin.Meanwhile being
During the transplantation process, Thermal ischemia reperfusion damages the influence to liver function for further attenuating liver, and many scholars attempt filling
Corresponding pharmaceutically active substance is added in fluid injection, to restore the normal physiological function of liver in filling process, reduces hot ischemic
Damage of the reperfusion injury to liver organization, for example, protease inhibitors, epidermal growth factor and albumin and some plants
Object active constituent, ligustrazine, total paeony glycoside, Radix Angelicae Sinensis polysaccharide etc..However, room temperature machine perfusion system combines corresponding perfusion liquid,
Although influence of the Thermal ischemia reperfusion damage to liver function can be mitigated to a certain extent, expand the source for liver, on
It states perfusion system and still has many deficiencies, be irrigated as perfusion system still needs using the perfusion liquid containing blood, due to blood
Liquid needs come from and donor, this equally also limits the range of materials.Meanwhile rejection will increase using the perfusion liquid containing blood
Risk and infection risk, moreover, its for hot ischemic tolerance degree also up for further improving.
Therefore, liver can be enhanced for the tolerance degree of hot ischemic by obtaining one kind, expanded for liver source, made liver in machine
The room temperature machine perfusion system for restoring physiological activity in tool filling process as soon as possible, is current urgent problem.
Summary of the invention
The present invention makes liver restore physiological activity as soon as possible during machine perfusion to solve expansion for liver source
Problem provides a kind of room temperature machine perfusion system for being applicable in Liver Allograft Preservation, which is characterized in that the machine perfusion system includes
Central Processor Module, Power Component, liver storage assembly, liquid circulation component, monitoring assembly and liquid collection assembly, it is described
Liquid circulation component includes liver perfusate memory, is stored with liver perfusate in the liver perfusate memory, described
Liver perfusate contains naringenin derivative, and does not contain red blood cell.
In one embodiment, the Central Processor Module is connect with monitoring assembly, for handling monitoring assembly institute
The data information of collection.
In one embodiment, the Central Processor Module is connect with Power Component and liquid circulation component connects,
For controlling the power of Power Component output, to control the reperfusion mode of the perfusion liquid of perfusion, flow velocity is perfused in injection pressure, is filled
The temperature and perfusion liquid oxygenation efficiency of note.
In one embodiment, the Central Processor Module is connect with liver storage assembly, is perfused for controlling
Temperature in journey.
In one embodiment, the monitoring assembly is connect with liquid circulation component and liver storage assembly, for supervising
Reperfusion mode, injection pressure and the data information that flow velocity is perfused of control and temperature, perfusion liquid in collection filling process.
In one embodiment, the Power Component is connect with liquid circulation component, for providing power to perfusion liquid.
In one embodiment, the liquid circulation component is connect with liver storage assembly, for transmitting perfusion liquid
Plantlet in vitro liver is given, and filters perfusion liquid for being recycled.
In one embodiment, the liquid collection assembly is connect with liver storage assembly, is being filled for collecting liver
The secretion generated during note, for example, bile；The liquid collection assembly is connect with monitoring assembly, is collected with monitor component
The incremental data of the secretion generated in filling process.
In one embodiment, the Power Component includes perfusion power device, it is preferred that the perfusion power device
For peristaltic pump or occlusion pump or artificial blood pump commonly used in the art, for example, Pneumatic blood pump, electric-liquid type blood pump etc..The filling
Note power device can provide duration perfusion power or pulsed perfusion power.
In one embodiment, the liver storage assembly includes liver storage device, the liver storage device packet
Internal layer and outer layer are included, includes temperature-adjusting device, preferably, the temperature-adjusting device in the interlayer between internal layer and outer layer
For the cold and hot regulation pipe in interlayer.Be provided with device for monitoring temperature in the temperature-adjusting device, the device for monitoring temperature with
Central processing unit connection, for collecting the temperature in liver storage device temperatures information and control collection liver storage device.
In one embodiment, the liquid circulation component includes apparatus of oxygen supply, and the apparatus of oxygen supply is preferably film oxygen
Clutch, artificial lung or membrane lung, the effect of apparatus of oxygen supply are to make perfusion liquid become oxygen to perfusion liquid offer oxygen and close perfusion liquid,
The oxygen for maintaining physiological function is provided during perfusion for liver cell.
In one embodiment, the liquid circulation component further includes that perfusion liquid filter device and perfusion liquid conveying are logical
Road.The perfusion liquid filter device is used to filter the impurity in perfusion liquid and the metabolic waste of liver generation, the perfusion liquid warp
It is recycled after filtering.
In one embodiment, the liquid circulation component further includes perfusion liquid transfer passage.The perfusion conveying is logical
Road includes input pipe and output duct, for inputting fresh liver perfusate to Plantlet in vitro liver and from Plantlet in vitro liver
Dirty middle output perfusion liquid.The input pipe is Y-type conduit, and one end is two conduits, respectively at for hepatic arterial infusion liquid
The input of input and portal vein perfusion liquid, it is preferred that the liver perfusate memory in the liquid circulation component passes through input
Conduit is connect with the liver storage device in liver storage assembly.
In one embodiment, the monitoring assembly includes temperature sensor, pressure sensor, flow sensor and body
Product meter, for monitoring the injection pressure of the temperature in filling process, perfusion liquid, liver in flow velocity and filling process being perfused
The quantity of the secretion of generation.
In one embodiment, the Central Processor Module includes control assembly and data handling component, for locating
Manage injection pressure, the perfusion stream of all data of monitoring assembly monitored and temperature, perfusion liquid in control filling process
Speed and oxygenation efficiency.Further, the central processing unit further includes information carrying means, the monitoring assembly can be monitored
The data parameters arrived, wireless passes to external corresponding reception device.
In one embodiment mode, the liquid circulation component further includes liver perfusate memory, and the liver fills
Fluid injection memory includes temperature-adjusting device, and preferably, the liver perfusate memory includes internal layer and outer layer, internal layer and
It include temperature-adjusting device in interlayer between outer layer, preferably, the temperature-adjusting device is the cold and hot adjusting in interlayer
Pipe.Liver perfusate is stored in the liver perfusate memory, the liver perfusate contains naringenin derivative, and not
Contain red blood cell.
In one embodiment, the naringenin derivative is naringenin -7-O- acetic acid esters and naringenin -7-O- propionic acid
Ester, it is preferred that the naringenin derivative is naringenin -7-O- acetic acid esters.Naringenin (naringenin) is that one kind is deposited extensively
It is in plant and Chinese medicine, is the glucoside member of naringin, belongs to flavanone kind composition, there is antibacterial, anti-inflammatory, removing freely
Base, anti-oxidant, cough-relieving apophlegmatic, reducing blood lipid, anticancer be antitumor, spasmolysis and cholagogue, prevents and treats hepatopathy, inhibits blood platelet solidifying
It ties, resist the effects of athero- artery sclerosis, be widely used in the fields such as medicine, food at present, current study show that, naringenin
It is able to suppress inflammatory factor storm caused by TNF-a etc., reduces tissue damage.But most of flavonoids such as naringenin
The fat-soluble and water solubility of object is poor, and bioavilability is low, by repairing to naringenin or other flavone compound structures
Decorations introduce fat-soluble or water soluble group, and fat-soluble or water-soluble, improvement life can be improved under the premise of guaranteeing physiological activity
Object availability.Naringenin -7-O- acetic acid esters and naringenin -7-O- propionic ester are by using " Benzylation-hydrolysis-acylation-plus hydrogen
Reduction " four step chemical synthesis synthesis, the solubility of two kinds of derivatives in water be respectively 637.34 ± 53.23 μ g/mL and
59.74 ± 4.81 μ g/mL, be above naringenin solubility (" naringenin -7-O- acetic acid esters and naringenin -7-O- propionic ester
Preparation and platelet aggregation inhibitory activity ", Xue Min etc., research and development of natural products, Dev 2016,28:1273-1278).
In one embodiment, the liver perfusate also contains biological enzyme, and the biological enzyme is preferably circumscribed glucosides
Enzyme, further preferably alpha-galactosidase and α-N- acetylglactoside enzyme, can remove the blood group antigens of cell surface,
For example, A, B antibody, prevent acute rejection and reduction chronic rejection occur during liver transplant.
In one embodiment, the liver perfusate includes artificial blood, and institute's artificial blood is preferably artificial to be closed
At the fluorocarbons with function of carrying oxygen.The colloid submicron emulsion that fluorocarbon emulsion is made of perfluorochemical has good
Good oxygen carrying capacity.Under the conditions of a certain concentration and partial pressure of oxygen, oxygen solubility is 20 times of water, 2 times higher than blood.As people
Work blood has perfluoro-n-butyl group furans, perfluorotributylamine, fluorine to arrange high E4, perfluorodecalin, perfluor first using preferable fluorocarbons
Base naphthalane, perfluamine etc..The artificial blood carries oxygen, maintains the physiological function of cell.Preferably, institute's artificial blood
For perfluorinated hydrocarbon (PFC).
In one embodiment, the liver perfusate further comprises colloid, lecithin, atriphos, pancreas islet
Element, Amino Acid Compound Injection 18AA, antibiotic, glucose, physiological saline, 10% Klorvess Liquid, 5% sodium bicarbonate are molten
Liquid, 10% calcium chloride solution, vitamin B12, vitamin E, vitamin C, dexamethasone, Alprostadil.The colloid is preferably
PEG, hydroxyl starch or 20% albumin.The antibiotic be preferably penicillin, ampicillin, Cefuroxime Sodium or this field
The common cephalosporin analog antibiotic known.
The physiological saline, potassium chloride, calcium chloride, sodium bicarbonate solution are the main electrolyte ingredient in human body, can be with
It maintains the osmotic pressure of perfusion liquid close to the blood plasma with human body, provides a good liquid environment for liver, wherein 5% carbonic acid
Hydrogen sodium can neutralize organ in acquisition process and preceding acidic materials a large amount of as caused by anaerobic metabolism are perfused, and stablize perfusion liquid
In pH value；Physiological saline can increase perfusion liquid capacity, as the primary solvent of perfusion liquid, while can provide stable crystal
Osmotic pressure makes perfusion liquid be in isotonic state.
The lecithin plays booster action for the emulsification or dispersion of artificial blood.The PEG, hydroxyl starch or 20%
Albumin can maintain the osmotic pressure of perfusion liquid as colloid, and preventing from being perfused for a long time causes liver cell showing for oedema occur
As.The atriphos (ATP) is the energy matter of cell, and phase needed for physiology being provided for liver cell should be able to
Amount.The vitamin B12, vitamin E, vitamin C provide corresponding substance, and vitamin C for the metabolism of liver cell
There is anti-oxidation function with vitamin E, liver oxidative damage caused by free radical caused by filling process can be reduced.
There are many different type amino acid to form for the Amino Acid Compound Injection, and amino acid is the important of protein and peptide
Component part provides metabolism substrate for the protein synthesis of in vitro liver.Antibacterials penicillin, ampicillin or cephalo furan
Pungent sodium etc., to a certain extent prevention infection.
The insulin promotes glucose to intracellular transfer, and protein is promoted to synthesize；The glucose is in vitro device
The energetic supersession of official provides substrate, is main energy sources；The dexamethasone can be mitigated with stabilizing cell membrane and organelle film
Organ inflammation's reaction.Blood vessel in the expansible organ of institute's Alprostadil improves microcirculation of the perfusion liquid inside liver.
In one embodiment, the liver perfusate is preferably every 1000ml perfusion liquid composition are as follows: naringenin -7-O-
Acetic acid esters 200-400mg, hydroxyl starch 2-6g, atriphos 20-40g, artificial blood 15-45g, lecithin 2-6g, gala
Glycosidase 1-2mg, acetylgalactosamine enzyme 1-2mg, Insulin 3 0-60u, Amino Acid Compound Injection 18AA 100-300ml,
Antibiotic 1-5g, glucose 5-30g, physiological saline 100-300ml, 10% potassium chloride 5-15ml, 5% sodium bicarbonate 10-30ml,
10% calcium chloride 10-20ml, vitamin B12 3-8mg, vitamin E 2-6mg, vitamin C 1-5mg, dexamethasone 1-6mg,
Alprostadil 5-15 μ g；Further preferred naringenin -7-O- acetic acid esters 325mg, hydroxyl starch 2.6g, atriphos 30g, people
Work blood 36g, lecithin 4g, galactosidase 1.25mg, acetylgalactosamine enzyme 1.25mg, insulin 43u, amino acid
Injection 18AA 150ml, antibiotic 2.5g, glucose 28g, physiological saline 200ml, 10% potassium chloride 15ml, 5% bicarbonate
Sodium 25ml, 10% calcium chloride 20ml, vitamin B12 4.2mg, vitamin E 3.6mg, vitamin C 2.5mg, dexamethasone
4.6mg, 10 μ g of Alprostadil, the solvent are water.
In one embodiment, the room temperature machine perfusion system for being applicable in Liver Allograft Preservation can be used to save isolated liver
It is dirty, it is preferred that storage temperature is to be stored at room temperature, for example, 25 DEG C -37 DEG C.It is furthermore preferred that described, the donor experience of in vitro liver
Heart stopping collecting or hot ischemic, for example, the time of hot ischemic or heart stopping collecting is 30-120min.
Compared with prior art, present invention has the advantage that the room temperature machinery suitable for Liver Allograft Preservation of the invention fills
Injection system uses special liver perfusate, which has good anti-oxidant, removing free radical, and inhibition filling process is scorching
The effects of sex factor storm, makes liver that can prevent ischemical reperfusion injury in Plantlet in vitro, makes liver in Plantlet in vitro mistake
Good physiological activity state is kept in journey, meanwhile, the room temperature machine perfusion system suitable for Liver Allograft Preservation of the invention can
Greatly extend liver for the tolerance degree of hot ischemic, and after Long Time Thermal ischemic or donor's heart stop winning, through being perfused simultaneously
It is transplanted in receptor body, normal physiological activity can be maintained and immunogenicity is lower, be not in acute rejection.The present invention
The source that liver donor can be greatly extended suitable for the room temperature machine perfusion system of Liver Allograft Preservation, can be good at solve liver
There are the problem of dirty donor source deficiency good market prospects and public and social interest to be worth.
Detailed description of the invention
Fig. 1: schematic diagram of the present invention for the machine perfusion system of Liver Allograft Preservation, wherein 1: Central Processor Module, 2:
Peristaltic pump, 3: liver perfusate memory, 4: input pipe A, 5: membrane oxygenator, 6: input pipe B, 7: input pipe C, 8: liver
Dirty storage device, 9: output duct A, 10: perfusion liquid filter device, 11: output duct B；12: fluid collection device, 13: liquid
Meter, 14: liver room temperature machine perfusion system, 15: monitoring data collection device, 16: temperature sensor, 17: pressure sensing
Device, 18: flow sensor, 19: data processing equipment, 20: control assembly, 21: information carrying means；
Fig. 2: Bcl-xl ImmunohistochemistryResults Results figure, wherein Figure 1A is the ImmunohistochemistryResults Results of perfusion liquid A group Bcl-xl expression,
Figure 1B is the ImmunohistochemistryResults Results of perfusion liquid B group Bcl-xl expression；
Fig. 3: Bax ImmunohistochemistryResults Results figure, wherein Fig. 2A is the ImmunohistochemistryResults Results of perfusion liquid A group Bax expression, and Fig. 2 B is
The ImmunohistochemistryResults Results of perfusion liquid B group Bax expression.
Specific embodiment
Below by way of preferred forms of the invention to the structure of the machine perfusion system for Liver Allograft Preservation of the invention
It is described in detail at effect, still, the following contents should not be construed as limiting the scope of the invention.
Embodiment 1 is suitable for the composition and connection type of the room temperature machine perfusion system of Liver Allograft Preservation
As shown in Figure 1, Central Processor Module (1) is connect with peristaltic pump (2), passes through center in perfusion system (14)
The output power of control assembly (20) control peristaltic pump 2 in processor module (1), the peristaltic pump (2) pass through output power
Variation control perfusion liquid injection pressure and flow velocity, further, peristaltic pump (2) is connect with liver perfusate memory (3), institute
Stating liver perfusate memory (3) is inside and outside two layers, is provided with cold and hot regulation pipe between ectonexine, the cold and hot regulation pipe is by controlling
Component (20) control processed, for adjusting the temperature of perfusion liquid；Liver perfusate memory is provided with temperature sensor in (3)
(16), for monitoring the temperature of liver perfusate；Liver perfusate memory (3) passes through input pipe A (4) and membrane oxygenator
(5) it connects, flow sensor (18) is provided between liver perfusate memory (3) and membrane oxygenator (5), for monitoring liver
The oxygenation efficiency of the overall flow rate of perfusion liquid, the membrane oxygenator (5) passes through the control assembly (20) in Central Processor Module (1)
It is controlled；Membrane oxygenator (5) is connect by input pipe B (6) and input pipe C (7) with liver storage device (8), described
Input pipe B (6) is hepatic arterial infusion conduit, flow sensor (18) and pressure sensor (17) is provided with, for supervising
Control the flow velocity and perfusion hydraulic coupling of hepatic arterial infusion；The input pipe C (7) is portal vein input pipe, thereon same setting
There are flow sensor (18) and pressure sensor (17), for monitoring the flow velocity and perfusion hydraulic coupling of portal vein perfusion；Liver is deposited
Be provided with opening in storage device (8), input pipe B (6) and input pipe C (7) can enter liver storage device (8) it is internal with
The liver of Plantlet in vitro connects.The liver storage device (8) is inside and outside two layers, and the interlayer between ectonexine is provided with cold and hot tune
Section pipe, the cold and hot regulation pipe is controlled by control assembly (20), for adjusting the interior environment temperature of liver storage device (8)；Liver
Temperature sensor (16) are provided in dirty storage device (8), for monitoring interior environment temperature.
The liver storage device (8) is connect by output duct A (9) with perfusion liquid filter device (10), liver storage
Opening is provided in device (8), output duct A (9) can enter inside liver storage device to be connect with the liver of Plantlet in vitro；
The perfusion liquid filter device (10) connect with liver perfusate memory (3), and the perfusion liquid that filtering is completed is recycled to liver
Perfusion liquid memory (3)；The liver storage device 8 is connect by output duct B (11) with fluid collection device (12), is used for
Collect the bile that liver is secreted in filling process；It is provided with liquid meter (13), uses in the fluid collection device (12)
In the Amount of Bile that metering liver is secreted in filling process.
Further, perfusion system (14) is provided with monitoring data collection device (15), the monitoring data collection device
(15) it collects caused by temperature sensor (16), pressure sensor (17) and flow sensor (18) and liquid meter (12)
Monitoring data, and the data of collection are transmitted to Central Processor Module (1).The Central Processor Module (1) is provided with
Data processing equipment (19), for handling monitoring data collected by monitoring data collection device (15), Central Processor Module
(1) further include information carrying means (21), the data processing equipment (19) can be handled into data parameters as a result, passing to outer
The corresponding reception device in portion.
Further, it is stored with liver perfusate in the liver perfusate memory (3), the liver perfusate is every
1000ml perfusion liquid composition are as follows: naringenin -7-O- acetic acid esters 200-400mg, hydroxyl starch 2-6g, atriphos 20-40g,
Acetylgalactosamine enzyme 1-2mg, Insulin 3 0-60u, artificial blood 15-45g, lecithin 2-6g, galactosidase 1-2mg are answered
Square amino acid injection 18AA 100-300ml, antibiotic 1-5g, glucose 5-30g, physiological saline 100-300ml, 10% chlorine
Change potassium 5-15ml, 5% sodium bicarbonate 10-30ml, 10% calcium chloride 10-20ml, vitamin B12 3-8mg, vitamin E 2-
6mg, vitamin C 1-5mg, dexamethasone 1-6mg, Alprostadil 5-15 μ g.
The acquisition and perfusion of 2 donor liver of embodiment
1 experimental animal
Male China's miniature pig 20-25 head, 30 ± 3Kg of weight.All experimental animals are treated by humanitarianism, symbol
It closes " management of laboratory animal and guide for use " that U.S. National Institutes are promulgated, experimental program obtains relevant experimental animal ethics committee
The license of member.
2. method
(1) experimental animal pre-operative anxiety is prohibited water 8 hours.Intramuscular injection yellow Jackets carry out induced anesthesia, weigh weight
And it records.Dorsal position four limbs are taken to be fixed on operating table, high flow capacity oxygen uptake, preserved skin connects precordial leads cardiac monitoring, pigtail end
Connect blood oxygen saturation probe.Scalp acupuncture is established peripheral vein access through auricular vein and is sufficiently fixed, before trachea cannula, chlorination
Scoline injection (1mg/kg) anesthesia induction judges that connection Anesthesia machine is ventilated after being inserted into correct position, keeps inspiratory/expiratory 1:
2.It remains of flaccid muscles through peripheral vein access interruption Vecuronium Bromide, give Propofol maintenance anesthesia.
(2) liver obtains: " ten " word notch successively into abdominal cavity, is dissected ligamentum hepatoduodenale, is given after free choledochus out
With ligation, proximal end plugs in catheter, separates out arteria hepatica, and portal vein is simultaneously suspended in midair, and whole section of arteria hepatica is completely free.And start to dissociate
Splenic vein starts free liver inferior caval vein out after the completion of splenic vein is free, then dissociate suprahepatic vena cava.After dissociating successfully from
Splenic vein is intubated to portal vein and completes, and starts free abdominal aorta, after the completion of abdominal aorta is free and is intubated, is injected intravenously heparin
12500 unit whole body test tube of hepari, after the completion of test tube of hepari, row liver perfusion uses UW liquid trans-portal vein groundwater increment about 500ml, abdomen
Aortic perfusion amount about 1000ml, biliary tract rinse about 150ml.Liver surface covers sterile ice bits constantly to help liver in filling process
It hepatectomizes after the completion of cooling perfusion, is placed in fill and be modified in 4 DEG C of sterile basins of protection liquid.
(3) preheating of machine perfusion system: using machine perfusion system, open system described in embodiment 1, make to be perfused
Liquid temperature and the temperature of liver locker room maintain 36.5 DEG C, keep Perfusion preservation system operating etc. to be accessed for liver.
(4) in vitro liver accesses perfusion system: when pulmonary preservation, relatively rich length of vessel is remained, it rapidly will be defeated
Enter conduit C (7) and input pipe B (6) insertion portal vein and arterial cannulation, avoids damage to.Output duct A (9) are accessed into liver,
Perfusate enters filter device (10) by output duct and is filtered, and is back to liver perfusion liquid device (3).Output is led
(11) one end pipe B is connect with liver bile duct, and the other end is connect with fluid collection device (12).
(5) Perfusion preservation: after the completion of connecting, adjustment arteria hepatica pressure 80~120mm Hg, portal venous pressure 10~
20mm Hg, perfusion total flow are maintained at 400-500ml/min, and oxygen flow/partial pressure of oxygen is maintained at 2-3L/min, and keeps being perfused
Liquid temperature is 36.5 DEG C.Portal vein, arteria hepatica stream are monitored by pressure sensor (17) and flow sensor (18) respectively in real time
Amount and pressure, the output power for adjusting peristaltic pump maintain the injection pressure and flow velocity of setting, portal vein and artery blood flow are maintained to exist
In scope of design.The method that every 3h takes equivalent to replace releases 400ml perfusion liquid and adds the fresh perfusion liquid of 400ml.
Influence of the 3 naringenin -7-O- acetic acid esters of embodiment to machine perfusion Plantlet in vitro liver
Naringenin (naringenin) has antibacterial, anti-inflammatory, removing free radical, anti-oxidant, cough-relieving apophlegmatic, reducing blood lipid, resists
Cancer is antitumor, spasmolysis and cholagogue, prevents and treats hepatopathy, inhibit coagulating platelets, resists the effects of athero- artery sclerosis, but its
Whether can be used in saving in vitro liver, especially whether its derivative naringenin -7-O- acetic acid esters can be used as perfusion liquid ingredient,
The machine perfusion for being conducive to liver saves, and at present and is unaware of.It is in vitro to machine perfusion in order to probe into naringenin -7-O- acetic acid esters
The influence of liver is saved, the present embodiment designs two different liver perfusates, and specific ingredient is as described in Table 1:
The ingredient of table 1 perfusion liquid A and perfusion liquid B constitutes (1000mL)
1. method for filling
Male China miniature pig 8,30 ± 3Kg of weight.Random two groups of grouping, A group and B group, every group 4.A group is using filling
Fluid injection A is irrigated preservation, and B group is irrigated preservations using perfusion liquid B, the acquisition of donor liver be perfused referring to embodiment 2,
Donor liver machine perfusion 9 hours in vitro.Experimental setup control group, it is small-sized for the male China without any experiment process
Pig.
2. the detection method of liver state
Aspartate transaminase (AST) and alanine aminotransferase (ALT) in 2.1 perfusion liquids
When taking perfusion 3h, 6h, 9h respectively, the perfusion liquid in output duct utilizes automatic clinical chemistry analyzer to carry out asparagus fern
Propylhomoserin transaminase (AST), the detection of alanine aminotransferase (ALT).The whole blood for taking the Chinese miniature pig of control group male, using it is complete from
Automatic Biochemical Analyzer carries out aspartate transaminase (AST), the detection of alanine aminotransferase (ALT).
2.2TUNEL method detects hepatocellular apoptosis
Experiment each group perfusion 9h takes liver organization formaldehyde to fix after shutting down；After control group is put to death, liver organization first is taken
Aldehyde is fixed.After pathology department carries out routine paraffin wax embedding treatment, slab is made in wax stone, slice is gently relied into ammonia with poly
Sour glass slide has been searched, and is placed in after 37 DEG C of roasting piece machine dries, is placed into before detection and bake 2 hours left sides of piece in 60 DEG C of oven
The right side measures liver cell using In situ terminal labeling (TdT-mediated dUTP nick end labeling, TUNEL) method
Apoptosis situation, viewed under light microscopy, each histotomy take 5 visuals field at random, in each same field of view using 520 ±
Green fluorescence number is observed and counted to 20nm wavelength, its average value is taken to represent apoptosis cell.It observes and counts using 620nm wavelength
Red fluorescence takes its average value as the visual field total number of cells.It is thin in apoptotic index (the AI)=Apoptosis number/visual field
Born of the same parents' sum × 100%.
The detection of 2.3 liver cell Bax and Bcl-2
Experiment each group perfusion 9h takes liver organization formaldehyde to fix after shutting down；After control group is put to death, liver organization first is taken
Aldehyde is fixed.After pathology department carries out routine paraffin wax embedding treatment, slab is made in wax stone, slice is gently relied into ammonia with poly
Sour glass slide has been searched, and is placed in after 37 DEG C of roasting piece machine dries, is placed into before detection and bake 2 hours left sides of piece in 60 DEG C of oven
The right side measures the content of cell Bax and Bcl-xl using the ImmunohistochemistryMethods Methods of this field routine, and calculates Bax/Bcl-xl ratio
Value.
The detection of inflammatory factor in 2.4 perfusion liquids
When taking perfusion 3h, 6h, 9h respectively, the perfusion liquid in output duct, the Chinese miniature pig of control group male takes whole blood, sternly
Lattice are measured according to the specification of commercialization Elisa kit.Detection project includes: tumour in perfusion liquid and control group whole blood
The variation of necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) content.
The detection of 2.5 bile productions
Respectively when 3h, 6h, 9h is perfused, the state and yield of bile in fluid collection device 12 are detected.
2.6 statistical procedures
Data processing is carried out using 13.0 statistical software of SPSS, mean compares using single factor test variance between multiple groups.P <
0.05 is statistically significant for difference.
3. experimental result
A group and B group are after perfusion 3h, 6h, 9h hours, aspartate transaminase (AST), and alanine aminotransferase (ALT) swells
Tumor necrosis factor-α (TNF-α), the content of interleukin-6 (IL-6) are as shown in table 2, and content data is averaged expression.
The changes of contents of different time points AST, ALT of table 2A group and B group, TNF-α and IL-6
The result shown from table 2 can be seen that using the perfusion perfusion containing naringenin -7-O- acetic acid esters, aspartic acid
Transaminase (AST), alanine aminotransferase (ALT), the content of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6)
Although being increased at perfusion initial stage, after perfusion after a period of time, all indexs are fallen after rise, and do not contain shaddock ped
The perfusion perfusion of element -7-O- acetic acid esters 9 hours, all indexs raising trend are obvious, this shows liver organization in filling process
In a degree of damage for being subject to.As it can be seen that naringenin -7-O- acetic acid esters inhibits inflammatory factor, reduces for removing free radical
The reperfusion injury and the in vitro good state of liver of maintenance of liver organization play the role of positive.
After A group and B group are perfused 9 hours, liver cell apoptotic index and Bax/Bcl-xl ratio content such as table 3, data
It is averaged expression.
3 liver cell apoptotic index of table and Bax/Bcl-xl ratio content
From table 3 it is observed that the liver organization of A group and B group after 9h is perfused, has occurred Apoptosis, but B group
Apoptosis ratio be apparently higher than A group, Bax and Bcl-xl are closely related with the apoptosis of liver cell, when Bax/Bcl-xl ratio
When higher, illustrate that the degree of Apoptosis is higher.As can be seen that the liver cell Bcl-xl table of A group from table 3 and Fig. 2-Fig. 3
Up to higher, Bax expression is then relatively low, and ratio is significantly lower than B group, and this also illustrates the liver cell apoptosis of A group is less.By
This is as it can be seen that naringenin -7-O- acetic acid esters also plays positive effect for the apoptosis of reduction liver cell.
By the state and yield discovery of bile in observation fluid collection device 12, start after being perfused in 3h, A group bile draws
Flow gradually increases, it is seen that more floccule；3h-8h bile is relatively stable, about 4.25ml/h, and floccule is reduced；After 8h is perfused
Amount of Bile decline, but still golden yellow, limpid bile is presented.And B group starts after being perfused in 3h, without apparent bile secretion, 3h-
There is a small amount of, bile and the relatively deep visible more floccule of bile color in 8h.This explanation, naringenin -7-O- acetic acid esters is for filling
During note, the lesion of stones in intrahepatic bile duct is prevented, also plays positive effect.
Influence of the content of naringenin -7-O- acetic acid esters for Liver Allograft Preservation in 4 liver perfusate of embodiment
In order to probe into influence of the content of naringenin -7-O- acetic acid esters in liver perfusate for Liver Allograft Preservation, this implementation
Example 3 kinds of different liver perfusates of design, specific ingredient are as described in Table 4:
The ingredient composition (1L) of 4 perfusion liquid C of table, perfusion liquid D, perfusion liquid E
1. method for filling
Male China miniature pig 12,30 ± 3Kg of weight.Random three groups of grouping, C group, D group, E group, every group 4.C group is adopted
It is irrigated preservation with perfusion liquid C, D group is irrigated preservation using perfusion liquid D, and the acquisition and perfusion of donor liver are referring to implementation
Example 2, donor liver machine perfusion 9 hours in vitro.Experimental setup control group is small for the male China without any experiment process
Type pig.
2. the detection method of liver state
When taking perfusion 3h, 6h, 9h respectively, the whole blood of perfusion liquid and the Chinese miniature pig of control group male in output duct,
It detects aspartate transaminase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-α), interleukin-6
(IL-6) content, specific detection method is referring to embodiment 3.
3. experimental result
C group, D group, E group are after perfusion 3h, 6h, 9h hours, aspartate transaminase (AST), alanine aminotransferase
(ALT), tumor necrosis factor-alpha (TNF-α), the content of interleukin-6 (IL-6) are as shown in table 5, and content data is averaged
Value indicates.
Table 5C group, D group, E group different time points AST, ALT, TNF-α and IL-6 changes of contents
The result shown from table 5 can be seen that compared with the control group, the liver of in vitro machine perfusion, at perfusion initial stage, respectively
Item Testing index is risen, and still, with the passage of infusion time, the effect of system and perfusion liquid is perfused in the application
Under, every Testing index is fallen after rise to close to normal level, and wherein the effect of perfusion liquid E is the most obvious, this explanation, in perfusion liquid
Naringenin -7-O- acetic acid esters the effect of middle addition 325mg/L is best.
Influence of the different warm ischemia time of embodiment 5 in vitro Liver Allograft Preservation
After probing into hot ischemic of the perfusion liquid E for experienced different time, repair for liver function, this
Embodiment is used as using the liver of 1h and 2h after heart stopping collecting for liver, is perfused respectively 9 hours using perfusion liquid E.
1. the acquisition of donor liver
Male China miniature pig 8,30 ± 3Kg of weight.Random two groups of grouping, F group and G group, every group 8.
Anesthesia miniature pig is placed on cardio-pulmonary resuscitation machine, injection 1g KCl induces cardiac arrest, gives the heart after cardiac arrest
It announces dead without vital reaction within 5min after lung recovery (CPR) 30min, CPR, F group 1 hour after death, wins liver
Dirty, G group wins liver in 2 hours after death.The acquisition and perfusion of donor liver are referring to embodiment 2.
2. the detection method of liver state
When taking perfusion 3h, 6h, 9h respectively, the perfusion liquid in output duct is detected aspartate transaminase (AST), the third ammonia
Sour transaminase (ALT), the content of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), specific detection method referring to
Embodiment 3.
3. experimental result
F group, G group are after perfusion 3h, 6h, 9h hours, aspartate transaminase (AST), and alanine aminotransferase (ALT) swells
Tumor necrosis factor-α (TNF-α), the content of interleukin-6 (IL-6) are as shown in table 6, and content data is averaged expression.
Table 6F group, G group different time points AST, ALT, TNF-α and IL-6 changes of contents
Result of the knot based on table 6 can be seen that the increase with Ischemia Time, and liver rises in perfusion initial stage indices
Obviously, this illustrates that warm ischemia time is longer, and the damage of liver organization and liver function decline are obvious with regard to the moon, and perfusion liquid E is carried out
After perfusion in 9 hours, the indices of liver are fallen after rise obviously, this explanation, perfusion liquid E has the liver that experienced hot ischemic
Repair.At the end of perfusion, the indices of F group and G group, although having a certain difference, difference is simultaneously
It is not very big, this explanation, perfusion liquid E still has preferable repair for experienced the liver organization of Long Time Thermal ischemic.
The transplanting of 6 Plantlet in vitro liver of embodiment
In order to which the liver for the hot ischemic being further subjected to is transplanted to intracorporal effect, this reality after perfusion liquid E perfusion
Example is applied to be transplanted using F group liver in embodiment 5 and G group liver.
1. experimental animal
Male China miniature pig 8,30 ± 3Kg of weight.Random two groups of grouping, every group 4, as donor graft donor,
Wherein, H group: the liver transplant of F group is received；I group: the liver transplant of G group is received.
2. transplantation method
Into abdominal cavity, it is dynamic successively to dissect choledochus, liver for sessile receptor pig, anesthesia, preserved skin, disinfection, drape, " people " notched cut
Arteries and veins and portal vein are suspended in midair after the completion of dissection, and start to dissect liver superior and inferior vena cava, and dissociate arteria hepatica, and successively blocks
It cuts off arteria hepatica (into no liver phase), portal vein, infrahepatic vena cava and liver superior and inferior vena cava, after extracing liver, starts rapidly
Implantation is for liver；The liver superior and inferior vena cava that coincide is immediately begun to, after the completion of coincideing, starts to rinse portal vein and be coincide, open door
Vein and semi-open liver superior and inferior vena cava, the relatively steady rear Full-open liver superior and inferior vena cava of monitoring vital sign (terminate without liver
Phase), infrahepatic vena cava is opened after next successively coincideing again, arteria hepatica coincide after completing the above blood vessel, observes hepatic secretion
Bile (new liver function recovery) out, and start the choledochus that coincide, indwelling T-type Tube Drain goes out bile, successively closes abdomen, and it closes abdomen and completes, T
Type Tube Drain goes out bile, and vital sign is relatively steady, and operation is completed, and monitors vital sign, during which gives appropriate antibiotic, hormone
And the corresponding energy therapy of supplement, gradually simultaneously defecation removes ECG monitor after not occurring obvious rejection for feed.
3. the detection method of liver state after transplanting
Respectively extract liver transplantation after 14d whole blood, detect aspartate transaminase (AST), alanine aminotransferase
(ALT), the content of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), specific detection method is referring to embodiment 3.
3. experimental result
H group 1 postoperative to there is acute infection, dead；The success off lines of itself and 3, survival, and it is anti-not occur acute renal allograft rejection
It answers.
I group 1 fault due to surgical procedure, death；The success off lines of itself and 3, survival, and it is anti-not occur acute renal allograft rejection
It answers.
The 14th day, aspartate transaminase (AST) in blood after H group, I group liver transplantation, alanine aminotransferase (ALT),
Tumor necrosis factor-alpha (TNF-α), the content of interleukin-6 (IL-6) are as shown in table 7, and content data is averaged expression.
The content of AST, ALT in 14 days blood after table 7H group, the transplanting of I group, TNF-α and IL-6
It can be seen that liver 14 days after the transfer of H group and I group from the data of table 7, AST, ALT, TNF- in cipient blood
The content of α and IL-6 levels off to normal value.As can be seen from the above results, perfusion liquid E is irrigated reparation to hot ischemic liver
Afterwards, it still is able to reach the requirement of liver transplant.As it can be seen that perfusion liquid E can greatly enhance liver for the tolerance degree of hot ischemic,
Expand the source for liver.
Above the present invention is described in detail with a general description of the specific embodiments, but in the present invention
On the basis of, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Therefore, not
These modifications or improvements on the basis of deviation spirit of that invention, fall within the scope of the claimed invention.
Claims (10)
1. a kind of machine perfusion system for Liver Allograft Preservation, which is characterized in that the machine perfusion system (14) includes center
Processor module (1), peristaltic pump (2), liver perfusate memory (3), membrane oxygenator (5), liver storage device (8), liquid
Collection device (12), monitoring data collection device (15) are stored with liver perfusate in the liver perfusate memory (3),
The liver perfusate contains naringenin derivative, and does not contain red blood cell.
2. the machine perfusion system described in claim 1 for Liver Allograft Preservation, which is characterized in that the liver perfusate storage
Device (3) is inside and outside two layers, and the interlayer of inside and outside two interlayer is provided with cold and hot regulation pipe, for adjusting the temperature of perfusion liquid；Liver fills
Temperature sensor (16) are provided in fluid injection memory (3), for monitoring the temperature of liver perfusate.
3. the machine perfusion system of any of claims 1 or 2 for Liver Allograft Preservation, which is characterized in that state liver storage device
(8) it is inside and outside two layers, the interlayer of inside and outside two interlayer is provided with cold and hot regulation pipe, for adjusting the inner ring of liver storage device (8)
Border temperature；Temperature sensor (16) are provided in liver storage device (8), for monitoring interior environment temperature.
4. being used for the machine perfusion system of Liver Allograft Preservation described in claim 1-3 any one, which is characterized in that the liquid
Collection device (12) is provided with liquid meter (13), the Amount of Bile secreted in filling process for measuring liver.
5. being used for the machine perfusion system of Liver Allograft Preservation described in claim 1-4 any one, which is characterized in that the machinery
Perfusion system (14) also includes temperature sensor (16), pressure sensor (17), flow sensor (18).
6. being used for the machine perfusion system of Liver Allograft Preservation described in claim 1-5 any one, which is characterized in that central processing
Device assembly (1) includes control assembly (20) and data processing equipment (19), and the Central Processor Module (1) further includes information
Transmitting device (21).
7. the machine perfusion system as claimed in any one of claims 1 to 6 for Liver Allograft Preservation, which is characterized in that central processing
Device assembly (1) is connect with peristaltic pump (2), and peristaltic pump (2) is connect with liver perfusate memory (3), liver perfusate memory
(3) it is connect by input pipe A (4) with membrane oxygenator (5), membrane oxygenator (5) passes through input pipe B (6) and input pipe C
(7) it is connect with liver storage device (8), liver storage device (8) passes through output duct A (9) and perfusion liquid filter device (10)
Connection, perfusion liquid filter device (10) are connect with liver perfusate memory (3)；Preferably, the monitoring data collection device
(15) it collects caused by temperature sensor (16), pressure sensor (17) and flow sensor (18) and liquid meter (12)
Monitoring data, and the data of collection are transmitted to Central Processor Module (1).
8. the machine perfusion system as claimed in any one of claims 1 to 6 for Liver Allograft Preservation, which is characterized in that every 1000ml
Perfusion liquid composition are as follows: naringenin -7-O- acetic acid esters 200-400mg, hydroxyl starch 2-6g, atriphos 20-40g, artificial blood
Liquid 15-45g, lecithin 2-6g, galactosidase 1-2mg, acetylgalactosamine enzyme 1-2mg, Insulin 3 0-60u, compound amino
Acid injection 18AA 100-300ml, antibiotic 1-5g, glucose 5-30g, physiological saline 100-300ml, 10% potassium chloride 5-
15ml, 5% sodium bicarbonate 10-30ml, 10% calcium chloride 10-20ml, vitamin B12 3-8mg, vitamin E 2-6mg, dimension life
Plain C 1-5mg, dexamethasone 1-6mg, Alprostadil 5-15 μ g.
9. being used for the machine perfusion system of Liver Allograft Preservation described in claim 1-8 any one, which is characterized in that every 1000ml
Perfusion liquid composition are as follows: naringenin -7-O- acetic acid esters 325mg, hydroxyl starch 2.6g, atriphos 30g, perfluorinated hydrocarbon 36g,
Lecithin 4g, galactosidase 1.25mg, acetylgalactosamine enzyme 1.25mg, insulin 43u, Amino Acid Compound Injection 18AA
150ml, antibiotic 2.5g, glucose 28g, physiological saline 200ml, 10% potassium chloride 15ml, 5% sodium bicarbonate 25ml, 10%
Calcium chloride 20ml, vitamin B12 4.2mg, vitamin E 3.6mg, vitamin C 2.5mg, dexamethasone 4.6mg, Alprostadil
10μg。
10. the purposes of the machine perfusion system described in any one of claim 1-9 for Liver Allograft Preservation, which is characterized in that
The room temperature machine perfusion system for Liver Allograft Preservation can be used to save in vitro liver, it is preferred that storage temperature is room temperature
It saves, for example, 25 DEG C -37 DEG C；It is furthermore preferred that described, the donor of in vitro liver experienced heart stopping collecting or hot ischemic, for example,
The time of hot ischemic or heart stopping collecting is 30-120min, most preferably 120min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811392862.8A CN109511649B (en) | 2018-11-21 | 2018-11-21 | Normal-temperature mechanical perfusion system capable of expanding liver supply source |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811392862.8A CN109511649B (en) | 2018-11-21 | 2018-11-21 | Normal-temperature mechanical perfusion system capable of expanding liver supply source |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109511649A true CN109511649A (en) | 2019-03-26 |
| CN109511649B CN109511649B (en) | 2021-06-25 |
Family
ID=65776629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811392862.8A Active CN109511649B (en) | 2018-11-21 | 2018-11-21 | Normal-temperature mechanical perfusion system capable of expanding liver supply source |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109511649B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3829296A4 (en) * | 2018-07-30 | 2022-05-04 | Acorn Biolabs, Inc. | Compositions for transportation and/or cryopreservation of cells and/or tissues |
| US11528903B1 (en) | 2021-08-02 | 2022-12-20 | The First Affiliated Hospital, Sun Yat-Sen University | Ischaemia-free organ perfusion device and perfusion method |
| US11617364B2 (en) | 2021-08-25 | 2023-04-04 | The First Affiliated Hospital, Sun Yat-Sen University | Multi-organ repairing and transferring device without interrupting blood flow |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479972A (en) * | 2013-09-29 | 2014-01-01 | 四川大学华西医院 | Composition for resisting oxidation and preparation method and application thereof |
| CN103841824A (en) * | 2011-04-14 | 2014-06-04 | 特兰斯迈迪茨公司 | Organ care solution for ex-vivo machine perfusion of donor lungs |
| CN104996396A (en) * | 2015-07-27 | 2015-10-28 | 中山大学附属第一医院 | In-vitro liver perfusion preservation solution |
| CN105123670A (en) * | 2007-02-17 | 2015-12-09 | 哈佛学院董事会 | Compositions and method for tissue preservation |
| CN205124849U (en) * | 2015-10-13 | 2016-04-06 | 中国人民解放军第三〇九医院 | Separation liver normal atmospheric temperature or low control by temperature change temperature perfusion device |
| CN105660604A (en) * | 2016-02-04 | 2016-06-15 | 浙江大学 | Isolated liver perfusion system and method |
| CN107183009A (en) * | 2017-06-14 | 2017-09-22 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | Liver blood irrigates system |
| CN206603121U (en) * | 2017-02-17 | 2017-11-03 | 南京鼓楼医院 | A kind of isolated organ In vitro perfusion save set |
-
2018
- 2018-11-21 CN CN201811392862.8A patent/CN109511649B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105123670A (en) * | 2007-02-17 | 2015-12-09 | 哈佛学院董事会 | Compositions and method for tissue preservation |
| CN103841824A (en) * | 2011-04-14 | 2014-06-04 | 特兰斯迈迪茨公司 | Organ care solution for ex-vivo machine perfusion of donor lungs |
| CN103479972A (en) * | 2013-09-29 | 2014-01-01 | 四川大学华西医院 | Composition for resisting oxidation and preparation method and application thereof |
| CN104996396A (en) * | 2015-07-27 | 2015-10-28 | 中山大学附属第一医院 | In-vitro liver perfusion preservation solution |
| CN205124849U (en) * | 2015-10-13 | 2016-04-06 | 中国人民解放军第三〇九医院 | Separation liver normal atmospheric temperature or low control by temperature change temperature perfusion device |
| CN105660604A (en) * | 2016-02-04 | 2016-06-15 | 浙江大学 | Isolated liver perfusion system and method |
| CN206603121U (en) * | 2017-02-17 | 2017-11-03 | 南京鼓楼医院 | A kind of isolated organ In vitro perfusion save set |
| CN107183009A (en) * | 2017-06-14 | 2017-09-22 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | Liver blood irrigates system |
Non-Patent Citations (3)
| Title |
|---|
| GILSON SOARES DO NASCIMENTO等: "The acute effects of citrus flavanones on the metabolism of glycogen and monosaccharides in the isolated perfused rat liver", 《TOXICOLOGY LETTERS》 * |
| 田庆: "外切糖苷酶清除人体器官血型抗原的实验研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 郭菁菁等: "黄酮类化合物对动物实验性肝损伤保护作用的研究进展", 《中国药理学通报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3829296A4 (en) * | 2018-07-30 | 2022-05-04 | Acorn Biolabs, Inc. | Compositions for transportation and/or cryopreservation of cells and/or tissues |
| US11528903B1 (en) | 2021-08-02 | 2022-12-20 | The First Affiliated Hospital, Sun Yat-Sen University | Ischaemia-free organ perfusion device and perfusion method |
| US11617364B2 (en) | 2021-08-25 | 2023-04-04 | The First Affiliated Hospital, Sun Yat-Sen University | Multi-organ repairing and transferring device without interrupting blood flow |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109511649B (en) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maghrani et al. | Hypoglycaemic activity of Retama raetam in rats | |
| CN109511649A (en) | A kind of room temperature machine perfusion system that can expand for liver source | |
| JP2000344602A (en) | Preservative for animal cell or organ and its preservation | |
| CN108902132B (en) | A kind of machine perfusion system saved for isolated heart | |
| CN109511650A (en) | A kind of room temperature machine perfusion liquid that can expand for liver source | |
| CN101347422B (en) | Uses of salvianolic acid A in preventing and/or treating diabetes and complication | |
| Bellomo et al. | Normothermic extracorporeal perfusion of isolated porcine liver after warm ischaemia: a preliminary report | |
| RU2441608C1 (en) | Method for restoration and maintenance of vitality of an ischemically damaged donor organ | |
| US20180271087A1 (en) | Device for vascularized composite allotransplant preservation and use thereof | |
| Chien et al. | A simple technique for multiorgan preservation | |
| CN112370496A (en) | Application of effective components of Lycii folium in preparing medicine for preventing or treating hepatic fibrosis | |
| RU2423931C2 (en) | Method of recovering viability of ischemically affected donor organs | |
| Oldhafer et al. | Liver transplantation in pigs: a model for studying reperfusion injury | |
| US8283377B2 (en) | Method for inhibiting blood vessel stenosis | |
| Shumway et al. | Surgical aspects of cardiac transplantation in man. | |
| CN112155009A (en) | Human organ blood oxygenation system | |
| CN105616445A (en) | NK cell secreted protein eye drops for treating viral keratitis and preparation method and application thereof | |
| Gao et al. | Research progress on hepatic machine perfusion | |
| CN101601644A (en) | A kind of icariine injection and its production and application | |
| Pareja et al. | Hepatic cell transplantation. Technical and methodological aspects | |
| CN108524939B (en) | Mitochondrial complex I reversible inhibitor combines the purposes for preparing ischemical reperfusion injury protection drug with active oxygen scavenger | |
| An et al. | Development and evaluation of a new apparatus for continuous perfusion of isolated perfused pig heart | |
| Lombardi et al. | Membrane bioreactors as hybrid artificial pancreas: experimental evaluation | |
| CN100577180C (en) | Application of gambogicacid in preparing medication for restraining angiogenesis | |
| CN1555814A (en) | Extracting method of propolis effective component and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Jianhui Inventor after: Yang Zijiang Inventor after: Zheng Jun Inventor before: Yang Zijiang Inventor before: Zheng Jun Inventor before: Li Jianhui |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |